MedTrace Logo

Perioperative Pregabalin in Ureteroscopy: a Pilot

NCT03927781 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-04-19

Study results available
· View outcomes & findings →

Summary

The investigators propose a pilot clinical trial on the use of perioperative pregabalin in order to decrease ureteral stent related symptoms and decrease opioid usage after ureteroscopy with stent placement. Patients undergoing ureteroscopy with stent placement will receive a single dose of 300 mg pregabalin PO in the preoperative area. This work will assess safety and feasibility of studying this regimen at our institution, with the aim of performing a randomized, placebo-controlled, double-blinded study in the future.

Conditions

  • Nephrolithiasis
  • Urolithiasis
  • Perioperative/Postoperative Complications
  • Pain, Postoperative
  • Pain, Acute
  • Anesthesia
  • Urologic Diseases
  • Anesthesia Morbidity

Interventions

DRUG

Pregabalin 300mg

One 300mg capsule will be administered PO 1 hour before surgery

Sponsors & Collaborators

  • University of Missouri-Columbia

    lead OTHER

Principal Investigators

  • Katie Murray, DO · Assistant Professor

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2019-10-17
Completion
2020-10-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03927781 on ClinicalTrials.gov